Who
Jeannette Potts
Chief Legal Officer
Company insider
Files Form 4 as: Chief Legal Officer, uniQure; Officer, Forma Therapeutics Holdings.
In numbers
- Trades disclosed
- 36
- Buys
- 0
- Sells
- 7
- Bought
- $0
- Sold
- $735K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 18 Jun 2020
- Last trade
- 15 Jun 2026
- Last filed
- 17 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jun 2026filed 17 Jun 2026 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $145K5,237 at $27.67 | filing |
| 15 Jun 2026filed 17 Jun 2026 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $145K5,237 at $27.67 | filing |
| 4 Mar 2026filed 6 Mar 2026 | QURE uniQureBiotechnology | SEC FORM 4 Code A | —35,400 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $31K3,412 at $9.06 | filing |
| 4 Mar 2026filed 6 Mar 2026 | QURE uniQureoption or derivative · Biotechnology | SEC FORM 4 Code A | —57,200 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | QURE uniQureoption or derivative · Biotechnology | SEC FORM 4 Code A | —57,200 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | QURE uniQureBiotechnology | SEC FORM 4 Code A | —35,400 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $31K3,412 at $9.06 | filing |
| 2 Mar 2026filed 4 Mar 2026 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $85K8,578 at $9.95 | filing |
| 2 Mar 2026filed 4 Mar 2026 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $85K8,578 at $9.95 | filing |
| 16 Jun 2025filed 20 Jun 2025 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $71K4,670 at $15.14 | filing |
| 4 Mar 2025filed 5 Mar 2025 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $73K7,076 at $10.29 | filing |
| 3 Mar 2025filed 5 Mar 2025 | QURE uniQureoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 3 Mar 2025filed 5 Mar 2025 | QURE uniQureBiotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 13 Jun 2024filed 17 Jun 2024 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $24K4,781 at $4.98 | filing |
| 1 Mar 2024filed 5 Mar 2024 | QURE uniQureoption or derivative · Biotechnology | SEC FORM 4 Code A | —85,500 at $0.00 | filing |
| 1 Mar 2024filed 5 Mar 2024 | QURE uniQureBiotechnology | SEC FORM 4 Code A | —49,500 at $0.00 | filing |
| 13 Jun 2023filed 15 Jun 2023 | QURE uniQureoption or derivative · Biotechnology | SEC FORM 4 Code A | —81,300 at $0.00 | filing |
| 13 Jun 2023filed 15 Jun 2023 | QURE uniQureBiotechnology | SEC FORM 4 Code A | —47,100 at $0.00 | filing |
| 14 Oct 2022filed 14 Oct 2022 | Forma Therapeutics Holdingsoption or derivative | SEC FORM 4 Code D | —111,746 | filing |
News
Reviewing Alkermes (NASDAQ:ALKS) and uniQure (NASDAQ:QURE)QURE · tickerreport.com · 13 Oct 2026Vir Biotechnology (NASDAQ:VIR) vs. uniQure (NASDAQ:QURE) Critical ContrastQURE · dailypolitical.com · 11 Oct 2026
0 headlines in the last 90 days name Jeannette Potts; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.